Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies.

Authors

Arvid Cederlund, Nona Struyf, Lucia Rico Pizarro, Päivi Östling, Kristina Sonnevi, Björn Engelbrekt Wahlin, Tom Erkers

Published in

NPJ precision oncology. Volume 10. Issue 1. Jul 30, 2026. Epub Jul 30, 2026.

Abstract

Relapsed/refractory lymphoid malignancies lack effective treatment selection strategies. We evaluated high-throughput ex vivo drug profiling in 26 patients, achieving successful profiling in 22 cases. We found broad ex vivo resistance to conventional chemotherapy but sensitivity to BH3 mimetics. Notably, p53-aberrant samples showed increased sensitivity to dasatinib and PI3K inhibitors across subtypes. These findings demonstrate feasibility of functional precision medicine pipelines in lymphoid malignancies and identify actionable vulnerabilities warranting further investigation.

PMID:
42533058
Bibliographic data and abstract were imported from PubMed on 31 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.